India to Canada: Amikacin Export Trade Route

To import finished pharmaceutical formulations containing Amikacin into Canada, the following approvals and registrations are necessary:

• Drug Identification Number (DIN): Each pharmaceutical product must obtain a DIN from Health Canada, signifying that the product has been evaluated and authorized for sale in Canada.

• Drug Establishment Licence (DEL): Importers must hold a valid DEL, which authorizes the importation of specific drug categories. The DEL application should detail the foreign manufacturing sites and the activities performed there.

• Common Technical Document (CTD) Format: Submissions for product approval should be presented in the CTD format, encompassing modules such as Quality, Safety, and Efficacy.

• Timelines and Fees: Approval timelines and associated fees can vary. It's advisable to consult Health Canada's current fee schedule and service standards for precise information.

• Good Manufacturing Practices (GMP) Inspection: Health Canada mandates that foreign manufacturing facilities comply with GMP standards. This involves submitting evidence of GMP compliance, which may include inspection reports from recognized regulatory authorities or, if necessary, an inspection conducted by Health Canada.

Indian manufacturers exporting Amikacin formulations to Canada must adhere to the following GMP standards:

• GMP Certification: Manufacturers must demonstrate compliance with GMP standards equivalent to those outlined in Health Canada's guidelines. This includes maintaining comprehensive quality management systems, proper documentation, and adherence to standard operating procedures.

• Approved Facilities: Only manufacturing sites listed on the importer's DEL are authorized to supply products to Canada. It's essential for Indian exporters to ensure their facilities are registered and approved by Health Canada.

• Recent Inspections and Regulatory Actions: Health Canada conducts periodic inspections of foreign manufacturing sites to verify GMP compliance. Any non-compliance identified can lead to regulatory actions, including import restrictions.

In the past 18 months, several regulatory developments have impacted pharmaceutical exports to Canada:

• Implementation of Updated GMP Guidelines: As of April 1, 2024, Health Canada's updated GMP guidelines for sterile drugs (GUI-0119) came into effect, emphasizing stricter controls and quality assurance measures.

• Enhanced Mutual Recognition Agreements (MRAs): In 2025, Canada expanded its MRAs with select countries, facilitating streamlined GMP compliance recognition. However, as of March 2026, India is not included in these agreements, necessitating direct GMP compliance verification for Indian exporters.

• Policy Adjustments on Importation: In January 2026, Health Canada revised its importation policies, introducing more stringent documentation requirements for imported pharmaceutical products to ensure product safety and efficacy.

Staying informed about these regulatory changes is crucial for Indian exporters to maintain compliance and ensure uninterrupted access to the Canadian market.

In 2024, the Canadian aminoglycosides market, which includes antibiotics such as amikacin, was valued at USD 57.2 million and is projected to reach USD 73.0 million by 2030, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2030. Gentamicin was the largest revenue-generating product in 2024, while tobramycin is expected to be the fastest-growing segment during the forecast period.

The demand for amikacin formulations in Canada is driven by factors such as the prevalence of bacterial infections, an aging population, and substantial healthcare spending. Canada's universal health coverage ensures access to essential medications, further supporting the demand for antibiotics like amikacin. While specific data on domestic production versus imports of amikacin formulations are not readily available, the presence of imports from countries like India indicates a reliance on international suppliers to meet domestic demand.

Canada maintains a Most-Favored-Nation (MFN) import duty rate of 0% for pharmaceutical products under HS code 30049099, which includes amikacin formulations. This exemption aligns with Canada's policy to facilitate access to essential medicines. Additionally, Canada has free trade agreements (FTAs) with various countries, potentially offering preferential tariff rates for pharmaceutical imports. However, there is no specific FTA between Canada and India that affects pharmaceutical tariffs. As of March 2026, there are no anti-dumping duties imposed on amikacin formulations imported into Canada.

India is a notable supplier of amikacin formulations to Canada, with exports totaling $0.5 million USD across five shipments from two Indian manufacturers. This route accounts for 2.4% of India's total amikacin formulation exports, valued at $21.1 million. The primary Canadian importer is Marcan Pharmaceuticals Inc., which received shipments totaling $0.4 million USD.

While specific data on other major countries supplying amikacin formulations to Canada is not provided, the global aminoglycosides market includes significant contributions from regions such as the United States, the European Union, and China. India's competitive pricing and established pharmaceutical manufacturing capabilities position it as a key player in supplying amikacin formulations to Canada.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the world's generic drug supply. This extensive manufacturing capability includes a significant production of finished dosage forms containing Amikacin, such as injections. The country's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of November 2024, India had 134 FDA-registered facilities for finished dosage forms, underscoring its compliance with international quality standards.

India's Amikacin formulations are competitively priced compared to those from China and the European Union. While specific per-unit pricing data is proprietary, India's cost advantages stem from lower labor and operational expenses. Quality perception is high, with Indian manufacturers adhering to stringent regulatory standards, including FDA and WHO-GMP certifications. In contrast, China's pharmaceutical industry has faced scrutiny over quality concerns, and the EU's branded generics are often priced higher due to brand value and regulatory costs. Canada's regulatory framework accepts Indian pharmaceutical products, provided they meet Health Canada's standards, which many Indian manufacturers comply with.

India's pharmaceutical industry demonstrates robust manufacturing capacity for Amikacin formulations, supported by advanced packaging and cold chain logistics to ensure product integrity during transit. The track record of Indian manufacturers shows consistent regulatory compliance, with facilities regularly inspected and approved by international bodies. While no significant supply disruptions have been reported recently, ongoing investments in capacity expansion and technological upgrades further enhance supply reliability.

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a steady supply of Amikacin formulations.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers; negotiate terms that align with your demand forecasts and storage capabilities.

• Payment Terms: Standard payment terms in India-Canada pharmaceutical trade often include letters of credit or advance payments; establish clear terms to maintain financial security.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits, quality control assessments, and verification of regulatory compliance, to ensure supplier reliability.

• Regulatory Compliance: Ensure that selected suppliers have the necessary approvals from Health Canada and other relevant authorities to facilitate smooth importation and distribution within Canada.

1. Verify Health Canada Authorization: Confirm that the Amikacin formulation is authorized for sale in Canada, indicated by a valid Drug Identification Number (DIN) on the product label.

2. Obtain Drug Establishment Licence (DEL): Ensure your company holds a valid DEL for importing finished pharmaceutical products, as required by Health Canada.

3. Confirm Supplier's GMP Compliance: Verify that the Indian manufacturer complies with Good Manufacturing Practices (GMP) and possesses a valid GMP certificate.

4. Assess Quality Management Systems: Evaluate the supplier's quality management system to ensure it meets international standards, including procedures for quality control, documentation, and corrective actions.

5. Review Regulatory History: Investigate the supplier's regulatory history for any past violations, warning letters, or sanctions from regulatory bodies.

6. Conduct Risk Assessment: Perform a comprehensive risk assessment of the supplier, considering factors such as supply chain reliability, financial stability, and geopolitical risks.

7. Plan for On-Site Audit: Schedule an on-site audit of the supplier's manufacturing facility to verify compliance with GMP and other regulatory requirements.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory compliance.

3. GMP Certificate: Issued by the relevant regulatory authority, confirming the manufacturing facility complies with GMP standards.

4. Stability Data: Demonstrates the product's shelf life and stability under various environmental conditions, ensuring efficacy and safety throughout its intended use period.

5. Batch Records: Detailed documentation of the manufacturing process for each batch, ensuring traceability and consistency in production.

6. Drug Master File (DMF): Contains confidential, detailed information about the facilities, processes, and materials used in the manufacturing of the product.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organisation (CDSCO), indicating the product is approved for sale in the country of origin.

8. Insurance Certificates: Evidence of liability insurance coverage, providing protection against potential claims related to product quality or safety.

1. Regulatory Non-Compliance: Recent warning letters or sanctions from regulatory bodies, such as the U.S. FDA or WHO, indicating compliance issues.

2. GMP Certification Issues: Suspension or revocation of GMP certification due to non-compliance with manufacturing standards.

3. Unrealistically Low Pricing: Prices significantly below market rates, which may suggest compromised quality or use of substandard materials.

4. Lack of Stability Data: Inability or unwillingness to provide comprehensive stability data, raising concerns about product shelf life and efficacy.

5. Limited Export Experience: No history of exporting to North American markets, indicating potential unfamiliarity with stringent regulatory requirements.

6. Resistance to Audits: Hesitation or refusal to allow on-site audits of manufacturing facilities, suggesting possible compliance or quality issues.

1. Pre-Audit Desktop Review: Conduct a thorough review of the supplier's documentation, including quality manuals, SOPs, and previous audit reports, to identify potential areas of concern.

3. Post-Audit Corrective Actions: Document any deficiencies identified during the audit and require the supplier to implement corrective actions within a specified timeframe.

4. Annual Re-Qualification Process: Schedule annual audits to ensure ongoing compliance with regulatory requirements and quality standards.

5. Remote Monitoring Options: Utilize technology for virtual audits and continuous monitoring of the supplier's quality systems, especially when travel is restricted.

6. Cost Estimates and Timeline: Budget approximately $10,000 to $15,000 CAD for an on-site audit, including travel expenses, with the process typically taking 3 to 5 days.